Latest news and press releases about Twist Bioscience Corporation (TWST): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips.
Price
| Price | $205.00 |
| Market Cap | $12.8B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 26.41 |
| EV / EBITDA | -118.21 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -29.89% |
| Return on Invested Capital | -24.57% |
| Return on Assets | -20.33% |
| Gross Margin | 51.97% |
| Operating Margin | -31.91% |
| Net Margin | -31.66% |
Related companies: BGM · CLOV · EWTX · GPCR · GRDN · MESO · PRCT
Explore sector: Healthcare · Biotechnology
More sections of TWST: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks